Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Leukemia
|
December 26, 2001
Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation
T de Witte, F Pikkemaat, J Hermans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 7, 2021
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
M A Dimopoulos, P Moreau, E Terpos, et al.
Leukemia
|
December 3, 2016
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
I J F Hofman, M van Duin, E De Bruyne, et al.
Journal of Hematology & Oncology
|
January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, et al.
Leukemia
|
February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M A Dimopoulos, A Palumbo, M Attal, et al.
Leukemia
|
February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos, X Leleu, A Palumbo, et al.
Acta Clinica Belgica
|
December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium
M Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica
|
October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myeloma
R Schots, M Delforge, M André, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Leukemia
|
December 26, 2001
Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation
T de Witte, F Pikkemaat, J Hermans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 7, 2021
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
M A Dimopoulos, P Moreau, E Terpos, et al.
Leukemia
|
December 3, 2016
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
I J F Hofman, M van Duin, E De Bruyne, et al.
Journal of Hematology & Oncology
|
January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, et al.
Leukemia
|
February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M A Dimopoulos, A Palumbo, M Attal, et al.
Leukemia
|
February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos, X Leleu, A Palumbo, et al.
Acta Clinica Belgica
|
December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium
M Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica
|
October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myeloma
R Schots, M Delforge, M André, et al.
Page
of 11